title: Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.
abstract: Meningiomas account for up to 20 % of all primary intracranial neoplasms; although the majority of these have a benign course, as many as 5-10 % can display more aggressive behavior and a higher incidence of disease progression. The benefit of immediate adjuvant radiotherapy is still being debated for atypical and malignant meningiomas. This study aimed to retrospectively assess prognostic factors and outcome in 68 patients with atypical and malignant meningiomas. Sixty-eight meningioma patients were treated with radiotherapy after initial resection or for recurrence, between January 1993 and December 2011. Surgery was macroscopically complete in 80 % of the patients; histology was atypical and malignant in 51 patients and 17 patients, respectively. Mean dose of radiotherapy was 54.6 Gy. Fifty-six percent of all patients received radiotherapy after surgical resection, 26 % at the first relapse, and 18 % at the second relapse. Median follow-up was 6.7 years, (range 1.5-19.9 years). The 5- and 10-year actuarial overall survival (OS) rates were 74.1 and 45.6 %, respectively. At univariate analysis age >60 years, radiotherapy dose >52 Gy showed statistical significance, (p = 0.04 and p = 0.03, respectively). At the multivariate analysis radiotherapy dose >52 Gy maintained the statistical significance, (p = 0.037). OS of patients treated with radiotherapy at diagnosis was longer than the survival of patients treated with salvage radiotherapy; however this difference did not reach statistical significance when tested for the entire series or for the subgroups of grade 2 and grade 3 patients. The 5- and 10-year disease-free survival (DFS) rates were 76.5 and 69.5 %, respectively, and were significantly influenced by size >5 cm (p = 0.04) and grading (p = 0.003) on univariate analysis. At multivariate analysis, size and grading both remained significant prognostic factors, p = 0.044 and p = 0.0006, respectively. Grade ≤ 2 acute side effects were seen during radiotherapy treatment in 16 % of the patients, with no ≥ grade 3 acute toxicity, based on the Common Terminology Criteria for Adverse Events. In this mono-institutional retrospective study, age and radiotherapy dose were associated with a longer OS, while preoperative size and grading of the tumor influenced DFS. Although there were some advantages in terms of OS for patients treated with postoperative radiotherapy, the benefit did not reach the significance. Multicenter prospective studies are necessary to clarify the management and the correct timing of radiotherapy in such a rare disease.
authors.affiliation: Radioterapia, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50144, Florence, Italy, beatrice.detti@aouc.unifi.it.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Detti
authors.forename: Silvia
authors.initials: S
authors.lastname: Scoccianti
authors.forename: Vanessa
authors.initials: V
authors.lastname: Di Cataldo
authors.forename: Eleonora
authors.initials: E
authors.lastname: Monteleone
authors.forename: Samantha
authors.initials: S
authors.lastname: Cipressi
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Bordi
authors.forename: Gianni
authors.initials: G
authors.lastname: Pellicanò
authors.forename: Davide
authors.initials: D
authors.lastname: Gadda
authors.forename: Calogero
authors.initials: C
authors.lastname: Saieva
authors.forename: Daniela
authors.initials: D
authors.lastname: Greto
authors.forename: Guido
authors.initials: G
authors.lastname: Pecchioli
authors.forename: Annamaria
authors.initials: A
authors.lastname: Buccoliero
authors.forename: Marco
authors.initials: M
authors.lastname: Ceroti
authors.forename: Franco
authors.initials: F
authors.lastname: Ammannati
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Biti
mesh_terms: D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D008579:Meningioma / Q000401:mortality / Q000532:radiotherapy*; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000532:radiotherapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000401:mortality*; D012189:Retrospective Studies; D015996:Survival Rate
references.citation: J Neurooncol. 1996 Sep;29(3):197-205
references.pmid: 8858525
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):859-64
references.pmid: 22137023
references.citation: J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
references.pmid: 13406590
references.citation: J Neurosurg. 1997 May;86(5):793-800
references.pmid: 9126894
references.citation: J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80
references.pmid: 17766430
references.citation: Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93
references.pmid: 18294779
references.citation: Cancer. 1999 May 1;85(9):2046-56
references.pmid: 10223247
references.citation: J Neurosurg. 2011 Oct;115(4):811-9
references.pmid: 21699480
references.citation: Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50
references.pmid: 16145534
references.citation: Surg Neurol. 1986 Mar;25(3):233-42
references.pmid: 3945904
references.citation: J Neurosurg. 2012 Oct;117(4):669-75
references.pmid: 22900840
references.citation: Strahlenther Onkol. 2006 Nov;182(11):641-6
references.pmid: 17072521
references.citation: Radiother Oncol. 2001 Oct;61(1):65-70
references.pmid: 11578730
references.citation: Neuropathology. 2007 Apr;27(2):114-20
references.pmid: 17494511
references.citation: Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16
references.pmid: 15708260
references.citation: Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22
references.pmid: 8598358
references.citation: Cancer. 2002 Mar 1;94(5):1538-47
references.pmid: 11920512
references.citation: Neurosurgery. 2009 Jan;64(1):56-60; discussion 60
references.pmid: 19145156
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61
references.pmid: 10656373
references.citation: J Clin Neurosci. 2010 Nov;17(11):1362-6
references.pmid: 20800497
references.citation: J Neurosurg. 2012 Oct;117(4):679-86
references.pmid: 22920955
references.citation: Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):427-32
references.pmid: 19427553
references.citation: J Neurosurg. 1994 Feb;80(2):195-201
references.pmid: 8283256
references.citation: J Neurooncol. 1998 Apr;37(2):177-88
references.pmid: 9524097